Bonk (NASDAQ:BNKK) Director Buys $17,138.73 in Stock

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy bought 11,659 shares of Bonk stock in a transaction dated Thursday, July 2nd. The stock was purchased at an average cost of $1.47 per share, for a total transaction of $17,138.73. Following the purchase, the director owned 85,000 shares of the company’s stock, valued at approximately $124,950. This trade represents a 15.90% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mitchell Austin Rudy also recently made the following trade(s):

• On Monday, June 22nd, Mitchell Austin Rudy bought 7,500 shares of Bonk stock. The stock was purchased at an average price of $1.56 per share, with a total value of $11,700.00.
• On Tuesday, June 16th, Mitchell Austin Rudy purchased 2,500 shares of Bonk stock. The shares were purchased at an average cost of $1.32 per share, with a total value of $3,300.00.
• On Wednesday, June 10th, Mitchell Austin Rudy purchased 12,000 shares of Bonk stock. The shares were purchased at an average cost of $1.37 per share, with a total value of $16,440.00.
• On Thursday, April 9th, Mitchell Austin Rudy purchased 31,055 shares of Bonk stock. The shares were purchased at an average price of $2.82 per share, for a total transaction of $87,575.10.

Bonk Price Performance

Bonk stock opened at $1.28 on Friday. Bonk, Inc. has a 1-year low of $1.24 and a 1-year high of $46.90. The firm has a market capitalization of $10.24 million, a P/E ratio of -0.28 and a beta of 1.89. The company’s 50-day moving average is $1.78 and its 200 day moving average is $2.75.

Bonk (NASDAQ:BNKK) last announced its earnings results on Wednesday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.79 million for the quarter. Bonk had a negative net margin of 838.37% and a negative return on equity of 148.62%.

Institutional Investors Weigh In On Bonk

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp bought a new position in Bonk in the fourth quarter worth about $33,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Bonk during the fourth quarter valued at about $37,000. Jane Street Group LLC bought a new stake in shares of Bonk in the 4th quarter valued at about $96,000. Finally, Geode Capital Management LLC bought a new stake in shares of Bonk in the 4th quarter valued at about $128,000. Institutional investors own 12.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BNKK. Wall Street Zen upgraded Bonk from a “sell” rating to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings lowered Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Bonk

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.